Cocrystal Pharma Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC.(Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. (Check one): If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: As of August 13, 2026, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was approximately19,263,200. COCRYSTAL PHARMA, INC. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026 INDEX Part I - FINANCIAL INFORMATIONItem 1.Condensed Consolidated Balance SheetsF-1Condensed Consolidated Statements of OperationsF-2Condensed Consolidated Statements of Stockholders’ EquityF-3Condensed Consolidated Statements of Cash FlowsF-4Notes to the Condensed Consolidated Financial StatementsF-5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations3Item 3. Quantitative and Qualitative Disclosures About Market Risk10Item 4. Controls and Procedures10Part II - OTHER INFORMATIONItem 1. Legal Proceedings11Item 1. A. Risk Factors11Item 2. Unregistered Sales of Equity Securities and Use of Proceeds11Item 3. Defaults Upon Senior Securities11Item 4. Mine Safety Disclosures11Item 5. Other Information11Item 6. Exhibits11SIGNATURES122 Part I – FINANCIAL INFORMATION COCRYSTAL PHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except per share data) COCRYSTAL PHARMA, INC. COCRYSTAL PHARMA, INC. COCRYSTAL PHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(in thousands) COCRYSTAL PHARMA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSFOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025(in thousands, except share and per share data)(unaudited) 1. Organization and Business Cocrystal Pharma, Inc. (“we”, the “Company” or “Cocrystal”), a clinical stage biopharmaceutical company incorporated in Delaware, has beendeveloping novel technologies and approaches to antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of viral diseases in humans. By concentrating our research anddevelopment efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas. The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performingresearch and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and,ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets,secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Liquidity and going concern The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of Americaapplicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. TheCompany has incurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2026, the Company recordeda net loss of approximately $5,463 and used approximately $4,856 of cash in op